Cargando…

A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia

Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dao, Joseph, Saran, Savreen, Wang, Melody, Michael, Christina, Phan, Nhu-y, Bellon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954190/
https://www.ncbi.nlm.nih.gov/pubmed/36831911
http://dx.doi.org/10.3390/brainsci13020368
_version_ 1784894063217999872
author Dao, Joseph
Saran, Savreen
Wang, Melody
Michael, Christina
Phan, Nhu-y
Bellon, Alfredo
author_facet Dao, Joseph
Saran, Savreen
Wang, Melody
Michael, Christina
Phan, Nhu-y
Bellon, Alfredo
author_sort Dao, Joseph
collection PubMed
description Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ are often prescribed metformin and statins but its impact remains unsatisfactory. The use of aspirin (ASA) to decrease cardiovascular risk in the general population has been thoroughly investigated and clear guidelines are currently in place. Since adjuvant treatment with ASA could possibly decrease CVD risk and mortality in SCZ, we conducted a systematic review of the literature to determine the state of the current literature on this subject. Our systematic review points to gaps in the literature on CVD prevention in SCZ and illustrates an obvious need for further research. Although several studies have shown increased CVD risk in SCZ, to date, no research has been conducted on the utilization of CVD preventative treatment such as ASA for SCZ.
format Online
Article
Text
id pubmed-9954190
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99541902023-02-25 A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia Dao, Joseph Saran, Savreen Wang, Melody Michael, Christina Phan, Nhu-y Bellon, Alfredo Brain Sci Systematic Review Cardiovascular disease (CVD), including heart disease and stroke, continues to be the leading cause of death worldwide. Patients with mental health disorders, including schizophrenia (SCZ) are known to have an increased risk for CVD. Given the association with metabolic syndrome, patients with SCZ are often prescribed metformin and statins but its impact remains unsatisfactory. The use of aspirin (ASA) to decrease cardiovascular risk in the general population has been thoroughly investigated and clear guidelines are currently in place. Since adjuvant treatment with ASA could possibly decrease CVD risk and mortality in SCZ, we conducted a systematic review of the literature to determine the state of the current literature on this subject. Our systematic review points to gaps in the literature on CVD prevention in SCZ and illustrates an obvious need for further research. Although several studies have shown increased CVD risk in SCZ, to date, no research has been conducted on the utilization of CVD preventative treatment such as ASA for SCZ. MDPI 2023-02-20 /pmc/articles/PMC9954190/ /pubmed/36831911 http://dx.doi.org/10.3390/brainsci13020368 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Dao, Joseph
Saran, Savreen
Wang, Melody
Michael, Christina
Phan, Nhu-y
Bellon, Alfredo
A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title_full A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title_fullStr A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title_full_unstemmed A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title_short A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia
title_sort systematic review on the potential of aspirin to reduce cardiovascular risk in schizophrenia
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954190/
https://www.ncbi.nlm.nih.gov/pubmed/36831911
http://dx.doi.org/10.3390/brainsci13020368
work_keys_str_mv AT daojoseph asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT saransavreen asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT wangmelody asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT michaelchristina asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT phannhuy asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT bellonalfredo asystematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT daojoseph systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT saransavreen systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT wangmelody systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT michaelchristina systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT phannhuy systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia
AT bellonalfredo systematicreviewonthepotentialofaspirintoreducecardiovascularriskinschizophrenia